Market atlas / Mitochondrial / MitoQ

MitoQ (mitochondria-targeted antioxidant)

de-novosmall-moleculemitochondria-targeted-antioxidant

Stage by geography

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCH

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	RCT	2018-09-15	not published
UK	RCT	2010-11-01	not published
CH	RCT	not dated	not published

Biomarker trends

no biomarker readings yet

Studies

The studies on MitoQ, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Change from baseline in the MATRICS Consensus Cognitive Battery (MCCB) composite score at week 12	CH, US
Changes in flow-mediated dilation (FMD)	US
Changes in blood pressure reactivity	US
Changes in circulating reactive oxygen species	US
Changes in blood biomarkers of nitric oxide bioavailability	US
Change from baseline in endothelial function at 3 months	US
Changes in diastolic function	US
Modified Fatigue Inventory Scale (MFIS)	US
Changes in pulse wave analysis (PWA)	US
Changes in pulse wave velocity (PWV)	US

Connections

Trajectory

2010

MarketUK: rct (clinical trials (highest phase 2))

NCT01167088 · machine-extracted

2018

Relatedshares a mechanism with Coq10

NCT03166800 · machine-extracted

2018

ProfileMitoQ (mitochondria-targeted antioxidant)

NCT03166800 · machine-extracted

2018

MarketUS: rct (clinical trials (highest phase 2))

NCT03166800 · machine-extracted

2026

MarketCH: rct (clinical trials (highest phase 3))

NCT06191965 · machine-extracted

Get into the weeds: raw observations + provenance

mitoq_uk  2026-06-29  kind=geography_stage  verify=M
   MitoQ: a UK phase 2 trial [NCT01167088]
   source NCT01167088  https://clinicaltrials.gov/study/NCT01167088

mitoq_edge_coq  2026-06-29  kind=edge  verify=M
   MitoQ is a mitochondria-targeted ubiquinone (CoQ) derivative
   source NCT03166800  https://clinicaltrials.gov/study/NCT03166800

mitoq_facets  2026-06-29  kind=facets  verify=M
   MitoQ facets
   source NCT03166800  https://clinicaltrials.gov/study/NCT03166800

mitoq_us  2026-06-29  kind=geography_stage  verify=M
   MitoQ: US phase 2 trials [NCT03166800]
   source NCT03166800  https://clinicaltrials.gov/study/NCT03166800

ctsearch__CH__dev_mitoq  2026-07-10  kind=geography_stage  verify=M
   mitoquinone: 1 registered trial(s) in CH, highest phase 3 [NCT06191965]
   source NCT06191965  https://clinicaltrials.gov/study/NCT06191965